Orion Oyj (ORINY) Fair Value & Analysis
Healthcare · US · Market cap $10.7B
Orion Oyj
ORINY · US
Fair value as of: Jul 17, 2026
From 26 valuation models · updated 6 days ago
Share price +10.3% over the past month.
Price vs Fair Value (12 months)
12‑month range $20.94 – $43.02 · fair‑value band $19.87 – $53.00 · the $43.02 price screens above the $34.08 fair value. As of Jul 17, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Orion Oyj (ORINY) currently trades at $43.02, while our model-based Fair Value estimate is $34.08, implying the stock looks roughly 20.8% overvalued today. We read business quality at 69/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Orion Oyj generated revenue of $2.0B at a net margin of 27.1%. Revenue grew 17.8% year over year. It earns a return on equity of 48.4%. Net debt stands at $144M. Fundamentals as of Jul 17, 2026
Our scenario range runs from $19.87 (bear case) to $53.00 (bull case); at $43.02, the current price sits within that range. The share trades near its 52-week high and 41% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at -21%, ORINY screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 17, 2026. TTM = trailing twelve months.
About the company
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Orion Oyj reported revenue of $1.9B in FY2025 versus $1.0B in FY2021, a compound +16.1%/yr. Reported net income was $481M in FY2025, compounding +25.5%/yr from FY2021.
Is ORINY fairly valued? → Check now
Recent news
- Orion Group Half-Year Financial Report January–June 2026
- Orion Corporation’s financial reporting and Annual General Meeting in 2027
- 45,611 Orion Corporation A shares converted into B shares
- Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,131 | $447.74 | -60% |
| Johnson & Johnson, JNJ | 4,128 MXN | 159.68 MXN | -96% |
| AbbVie Inc ABBV | $230.01 | $133.86 | -42% |
| Roche Holding 1RO | €377.80 | €280.03 | -26% |
| Merck & Co MRCK34 | R$76.74 | R$50.09 | -35% |
| Novartis AG NVSN | 2,601 MXN | 1,897 MXN | -27% |
| AstraZeneca PLC ZEG | €160.70 | €128.63 | -20% |
| Novo Nordisk A/S NOVOB | kr 307.75 | kr 542.67 | +76% |
| Amgen Inc AMGN34 | R$63.24 | R$9.04 | -86% |
| Gilead Sciences, Inc GILD | 2,263 MXN | 2,010 MXN | -11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Orion Oyj (ORINY) undervalued?
What is the fair value of ORINY?
What is the quality score of ORINY?
What is the revenue of Orion Oyj (ORINY)?
What is the net profit margin of ORINY?
Does Orion Oyj pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Orion Oyj analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.